How to Get Vyleesi (Bremelanotide) in Washington State

What Is Vyleesi and Who Is It For?

Vyleesi is the brand name for bremelanotide, a melanocortin-4 receptor agonist that the FDA approved in June 2019 for treating HSDD in premenopausal women. The drug works by activating central nervous system pathways involved in sexual desire, rather than targeting peripheral blood flow. It is not indicated for postmenopausal women or for men.

HSDD affects an estimated 8 to 10 percent of women aged 20 to 49, according to a prevalence study published in Obstetrics & Gynecology. The condition is characterized by persistently low sexual desire that causes personal distress and is not better explained by another medical condition, a relationship issue, or a medication side effect. The International Society for the Study of Women's Sexual Health (ISSWSH) diagnostic criteria require both reduced desire and clinically significant distress lasting at least six months.

Bremelanotide differs from flibanserin (Addyi) in a key way: it is dosed on demand rather than daily. Patients self-inject 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with a maximum of 8 doses per month. That on-demand profile makes it practical for Washington residents who want treatment flexibility without a daily pill.

Clinical Evidence Supporting Bremelanotide

The approval of bremelanotide rested primarily on two phase 3 trials published together as the RECONNECT program (N=1,247). Across both studies, women using bremelanotide 1.75 mg reported a statistically significant increase in sexual desire and a decrease in distress compared with placebo over 24 weeks.

Specifically, the RECONNECT trials showed a mean increase of 0.35 on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13, compared with a 0.07 increase for placebo (P<0.001) [1]. The co-primary endpoint, change in the Female Sexual Function Index desire domain score, also favored bremelanotide over placebo [1]. The most common adverse event was nausea, occurring in roughly 40% of participants during initial dosing but declining to about 2% with continued use according to the FDA prescribing information.

A 52-week open-label extension of the RECONNECT data demonstrated sustained efficacy without evidence of tachyphylaxis, as reported in a follow-up publication [2]. Blood pressure changes were transient: a mean increase of 2 to 3 mmHg systolic occurred within 2 hours of dosing and resolved by 12 hours. The FDA label accordingly recommends against use in patients with uncontrolled hypertension or known cardiovascular disease.

How to Get a Vyleesi Prescription in Washington

Washington state law allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe Vyleesi. NPs in Washington hold full practice authority and can prescribe without a collaborative agreement, which broadens access in rural counties.

Three pathways exist for Washington residents:

In-person visit. A gynecologist, sexual medicine specialist, or primary care provider evaluates HSDD symptoms using validated tools such as the Decreased Sexual Desire Screener (DSDS). A focused history and targeted labs rule out alternative causes before the prescription is written.

Telehealth visit. Washington permits synchronous audio-video telehealth prescribing for Vyleesi. The Washington State Department of Health maintains parity rules requiring insurers to reimburse telehealth visits at the same rate as in-person care. This route is especially practical for patients in eastern Washington or the San Juan Islands, where sexual medicine specialists are scarce.

HealthRX telehealth platform. Board-certified clinicians licensed in Washington can evaluate HSDD symptoms, order labs electronically, and prescribe bremelanotide. Prescriptions are sent to the patient's pharmacy of choice or to a partner 503A compounding pharmacy.

Labs and Screening Before Starting Vyleesi

A prescriber should confirm the HSDD diagnosis and exclude medical mimics before writing bremelanotide. The Endocrine Society clinical practice guideline recommends the following baseline workup:

• TSH and free T4 to rule out thyroid dysfunction, a common cause of low libido.
• Prolactin to exclude hyperprolactinemia.
• Total and free testosterone to assess androgen status, particularly in women on hormonal contraceptives.
• Estradiol if perimenopause is suspected (bremelanotide is only indicated for premenopausal women).
• CBC and CMP as a general health screen, especially to assess renal and hepatic function before introducing a peptide drug.
• Blood pressure at baseline. The FDA label warns of transient hypertension post-dose.

A depression screening (PHQ-9) and medication reconciliation are also standard. SSRIs, SNRIs, and hormonal contraceptives are among the most common pharmacologic causes of reduced desire in premenopausal women, according to a 2016 review in the Journal of Clinical Endocrinology & Metabolism. A prescriber may recommend addressing these factors before or alongside bremelanotide therapy.

Insurance Coverage and Prior Authorization in Washington

Most commercial plans in Washington classify Vyleesi as a specialty medication and require prior authorization (PA). Washington Apple Health (Medicaid) covers Vyleesi with PA for premenopausal women with documented HSDD.

A successful PA submission typically requires:

1. A formal HSDD diagnosis (ICD-10 code F52.0).
2. Documentation of distress using a validated measure such as the FSDS-DAO.
3. Failure of, intolerance to, or clinical rationale against a trial of flibanserin (most payers require step therapy).
4. Lab results excluding organic causes (thyroid, prolactin, testosterone).
5. Confirmation that the patient is premenopausal.

PA turnaround is typically 3 to 5 business days for Washington commercial plans and up to 10 business days for Medicaid. If denied, the Washington Office of the Insurance Commissioner provides an external review process. Palatin Technologies offers a manufacturer copay program that may reduce out-of-pocket costs for commercially insured patients, bringing the copay to as low as $0 for eligible individuals.

Without insurance, the wholesale acquisition cost of brand-name Vyleesi is approximately $950 for a pack of four autoinjectors. Compounded bremelanotide from a 503A pharmacy is considerably less expensive, though pricing varies by pharmacy.

503A Compounding Pharmacies in Washington

Washington's Board of Pharmacy licenses 503A compounding pharmacies that can prepare bremelanotide as a patient-specific compound. Under FDA section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies may compound a drug that is commercially available (like Vyleesi) only when the prescriber documents a clinical difference for the individual patient, such as a need for a different concentration, preservative-free formulation, or alternative delivery method.

Several 503A pharmacies operating in or shipping to Washington offer bremelanotide in vials for subcutaneous injection at 1.75 mg/0.3 mL. Patients draw the dose using an insulin syringe. This route costs significantly less per dose than the brand-name autoinjector.

To fill a compounded bremelanotide prescription in Washington, you need:

• A valid prescription from a provider licensed in Washington specifying "compounded bremelanotide."
• The prescriber must note why the compounded version is clinically appropriate for the patient.
• The pharmacy must be licensed by the Washington State Board of Pharmacy and hold appropriate sterile compounding accreditation.

HealthRX partners with accredited 503A pharmacies that ship temperature-controlled bremelanotide directly to Washington addresses. Typical delivery time is 5 to 7 business days after the prescription is verified.

Self-Injection Technique and Dose Timing

Bremelanotide is injected subcutaneously into the abdomen or anterior thigh. The FDA-approved prescribing information specifies a single 1.75 mg dose administered at least 45 minutes before anticipated sexual activity.

Key administration points:

• Rotate injection sites to avoid lipodystrophy.
• Do not administer more than one dose in 24 hours.
• Do not exceed 8 doses in a calendar month.
• Nausea is the most common side effect. In the RECONNECT trials, 40% of women experienced nausea with the first dose, but this declined to under 3% by month 3 [1]. Taking an antiemetic (such as ondansetron 4 mg) 30 minutes before the first two to three injections can reduce initial nausea, as noted in clinical practice recommendations published in Sexual Medicine Reviews.
• Transient flushing, headache, and injection-site reactions each occurred in 10 to 20% of trial participants [1].

Patients using the brand autoinjector simply press the device against the skin and activate. Those using compounded vials draw 0.3 mL (1.75 mg) into an insulin syringe. Proper sharps disposal is required under Washington Administrative Code (WAC 296-823) for home-generated sharps.

Who Should Not Use Bremelanotide

The FDA label lists specific contraindications. Bremelanotide should not be used by women with:

• Uncontrolled hypertension. Transient blood pressure elevation post-injection (mean +2 to 3 mmHg systolic, +1 to 2 mmHg diastolic) was observed in phase 3 data [1]. Women with blood pressure above 140/90 mmHg at screening were excluded from the RECONNECT trials.
• Known cardiovascular disease. No dedicated cardiovascular outcome trial exists for bremelanotide, so the FDA mandated a postmarketing study to assess cardiovascular safety in higher-risk populations.
• Concurrent use of naltrexone. Bremelanotide may reduce the efficacy of mu-opioid receptor agonists. The FDA label specifically warns against coadministration with oral naltrexone due to a pharmacodynamic interaction reducing naltrexone effectiveness by approximately 50%, per a drug interaction study published in Clinical Pharmacology & Therapeutics.

Women who are postmenopausal, pregnant, or breastfeeding are not candidates for this medication. The drug has not been studied in these populations.

Timeline From First Visit to First Dose in Washington

The typical path from initial consultation to medication in hand follows this sequence:

• Day 1. Telehealth or in-person visit. HSDD screening, medical history, lab orders placed.
• Days 2 to 5. Lab results returned. Prescriber reviews and confirms diagnosis.
• Days 5 to 7. Prescription sent. If insurance PA is required, submitted on day 5.
• Days 7 to 14. PA decision received (3 to 5 business days for commercial, up to 10 for Medicaid). If approved, prescription routed to specialty or compounding pharmacy.
• Days 10 to 21. Medication arrives. Brand Vyleesi ships from a specialty pharmacy. Compounded bremelanotide ships from a 503A pharmacy with cold-chain packaging.

For patients paying out of pocket or using a compounding pharmacy without PA requirements, the timeline compresses to roughly 7 to 10 days.

Transferring a Vyleesi Prescription to Washington

Washington follows standard prescription transfer rules for non-controlled medications. Bremelanotide is not a DEA-scheduled drug, so transferring a prescription from another state is straightforward. The receiving pharmacy contacts the originating pharmacy, verifies the prescription, and processes the fill. The prescriber must hold an active license in the state where the prescription was originally written.

If the original prescription came from a provider not licensed in Washington and refills are needed, the patient will need to establish care with a Washington-licensed provider. Telehealth makes this simple. A single synchronous visit with a Washington-licensed clinician is sufficient to issue a new prescription.